tpiv200
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 6, 2016 (NCT02764333)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Folate receptor alphaImmunity, active
FOLR1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tpiv200
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02764333 | Phase 2 | May 6, 2016 | AstraZeneca, Cornell University, Tapimmune Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 0 | 1 | 2016 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Tapimmune Inc. | For profit | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1